Upneeq
Customize your policy alerts
Sign up for Cigna Policy IP0088 alerts
Get alerted when Policy IP0088 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage determinations for Upneeq (oxymetazoline hydrochloride 0.1% ophthalmic solution) under Cigna-administered health benefit plans and applies to providers, subject to the member's benefit plan, applicable laws, and individual clinical circumstances.
Coverage language was added stating that Upneeq is experimental, investigational, or unproven for blepharoptosis or conjunctivitis because of insufficient data establishing safety, efficacy, and improved health outcomes.
The policy wording for cosmetic use was revised to identify Upneeq use for blepharoptosis without functional limitation as not medically necessary.
The revision history states that no criteria changes were made in the subsequent policy updates.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.